The development and marketing of tourism destinations has increasingly focused on collaboration and community approach in which convention and visitors bureaus (CVBs) are playing important roles in coordinating marketing activities and developing desired image of the destination in the marketplace. However, the fulfillment of the CVB's destination marketing role has been challenged by a number of issues related to governance and positioning. Taking a case study approach, this study attempts to understand the roles and strategies of CVBs in collaborative destination marketing and assess the collaborative marketing relationships and activities between the CVB and local tourism businesses. Discussions and implications are provided based on the study results.

Question 1

1. Is it safe to give piracetam to patients with primary intracerebral

haemorrhage? Does it have a neuroprotective effect?

2. Is it safe to give a patient with excessively high blood pressure

(as a sequela to recent primary intracerebral haemorrhage)

angiotensin-converting enzyme inhibitors to lower the blood

pressure?

3. Is it indicated to give piracetam or vincamine to a patient with middle

cerebral artery territorial infarction? Do these have any neuroprotective

effect?

Question 2

What is the mechanism by which subarachnoid haemorrhage is

associated with subhyaloid haemorrhages on fundus examination, and

how can cerebrospinal fluid (CSF) gain access to the subhyaloid space

inside the eye?

Question 3

What is the recommended dosage for nimodipine given intravenously in

cases of subarachnoid haemorrhage, and when should the treatment

start? For how long should the dose be continued?

Question 4

I read recently that hyperuricaemia has something to do with stroke? Is it

recommended to give allopurinol to stroke patients irrespective of their

serum uric acid?

Question 5

Is there a link between hyperuricaemia (although asymptomatic) and

atherosclerosis and cerebral ischaemic stroke?

Question 6

Are phenytoin and carbamazepine indicated in myoclonus, occasionally

seen in ischemic strokes?

Question 7

What is the treatment of chorea or action myoclonus resulting from

embolic stroke to the area of basal ganglia? Does the L-dopa that is given

by some neurologists improve the condition? Does valproate have a role

if the case is action myoclonus?

Question 8

How should a patient with a haemorrhagic cerebrovascular accident

be managed while also having an extensive inferior wall myocardial

infarction?

Question 9

What is the best way to manage cortical vein thrombosis? If heparin is to

be used, what is the recommended dosage and how long should this

treatment last?

Question 10

In the case of cortical vein thrombosis, for how long should

anticoagulation be continued?217180